SynthesisBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica2018
Strontium ranelate as a possible disease-modifying osteoarthritis drug: a systematic review.
Synthesis in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 28 citations in OpenAlex.
- Remineralization Effect of a Strontium-Containing Composite: An In Vitro Study.Materials (Basel, Switzerland) · 2026Article
- Advances in the pathology and treatment of osteoarthritis.Journal of advanced research · 2025Review
- Article
- Coenzyme Q10 prevents RANKL-induced osteoclastogenesis by promoting autophagy via inactivation of the PI3K/AKT/mTOR and MAPK pathways.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- The Current Role of Disease-modifying Osteoarthritis Drugs.The archives of bone and joint surgery · 2023Review
- The anti-inflammation effect of strontium ranelate on rat chondrocytes with or without IL-1βExperimental and therapeutic medicine · 2022Article
- The role of TNFRSF11B in development of osteoarthritic cartilage.Rheumatology (Oxford, England) · 2022Article
- Biomaterials for Interbody Fusion in Bone Tissue Engineering.Frontiers in bioengineering and biotechnology · 2022Review
- Strontium ranelate promotes chondrogenesis through inhibition of the Wnt/β-catenin pathway.Stem cell research & therapy · 2021Article
- Chondroprotective effect of melatonin and strontium ranelate in animal model of osteoarthritis.Heliyon · 2021Article
- Advances in Osteoporotic Bone Tissue Engineering.Journal of clinical medicine · 2021Review
- Osseointegration of osteoporotic bone implants: Role of stem cells, Silica and Strontium - A concise review.Journal of clinical orthopaedics and trauma · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Considering that osteoarthritis (OA) is the most prevalent joint disease worldwide, multiple pharmacological treatments have been proposed to alter the articular structure with potential benefit in the progression of the disease. The so-called disease-modifying OA drugs have been frequently investigated but conclusive findings are rare. Strontium ranelate (SrRan) is a drug usually prescribed to treat osteoporosis, with proven effects in decreasing the risk of fractures and possible effect in reducing the progression of OA. The objective of this review was to demonstrate the current panorama of knowledge on the use of SrRan in clinical and experimental models, clarifying its mechanisms of action and describing possible anti-nociceptive and anti-inflammatory effects. The systematic review was based on the PRISMA statement and included articles that are indexed in scientific databases. Fifteen studies were included: seven pre-clinical and eight clinical studies. Despite the limited number of studies, the results suggest a positive effect of SrRan in patients with OA, through changes in functional capacity and reduction of progression of morphological parameters and joint degradation, with moderate quality of evidence for those clinical outcomes. Novel studies are necessary to elucidate the molecular targets of SrRan, focusing on anti-inflammatory effects and histological changes promoted by SrRan, which seemed to reduce the progression of OA in the experimental and clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.